Key result
Targeted 30-day IV antibiotics successfully cure isolated tricuspid valve endocarditis in a non-IVDU patient.
Why the study?
Isolated native nonrheumatic tricuspid valve endocarditis in nonintravenous drug users is rare.
Case Report (n=1)
No
Hypothesis-generating for shorter antibiotic courses in select non-IVDU right-sided endocarditis; does not support practice change without prospective trials.
Infective endocarditis (IE) is a disease characterized by high morbidity and mortality. IE was first described in the mid-16th century. Right-sided infective endocarditis (RSIE) represents 5% to 10% of all IE episodes in adults. RSIE can be divided into three groups according to the underlying risk factors: intravenous drug users (IDUs), cardiac device carriers, and the "three noes" group (no left-sided IE, no IDUs, and no cardiac devices). Tricuspid valve endocarditis in nonintravenous drug users can occur in a variety of conditions including congenital heart disease, intracardiac devices, central venous catheters, and immunologically debilitated patients. Due to the rareness of isolated native nonrheumatic tricuspid valve endocarditis, here, we like to present an 18-year-old male from rural Ethiopia with the diagnosis of isolated native tricuspid valve endocarditis that was treated and cured.
No takes yet. Share an insight, caveat, or question.
Shibru et al. (2020) conducted a case report in Isolated native tricuspid valve infective endocarditis (n=1). Intravenous antibiotics (ceftriaxone plus vancomycin switched to cloxacillin) and diuretics was evaluated on Clinical cure and hospital discharge without permanent cardiac sequelae. Intravenous antibiotic therapy for 30 days successfully cured an 18-year-old male non-intravenous drug user with Staphylococcus aureus isolated native tricuspid valve endocarditis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: